Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Invesco WilderHill Clean Energy ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Invesco WilderHill Clean Energy ETF trades at $25.75 (market cap $315.85M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 9.1× Invesco WilderHill Clean Energy ETF's market cap, and Invesco WilderHill Clean Energy ETF is more actively traded (452,833 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Invesco WilderHill Clean Energy ETF for 47 Days on average.
| DYN | PBW | |
|---|---|---|
Market Cap | $2.86B | $315.85M |
Volume | 3,341,579 | 452,833 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $46.99 |
52-Week Low | $14.60 | $25.77 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
The Invesco WilderHill Clean Energy ETF (PBW) trades at $27.33, down 0.33% on the day, with a bearish technical signal driven by moving averages. Key financial ratios such as P/E and P/S are not applicable for this ETF. Recent news highlights institutional selling, with IFP Advisors cutting its stake by 96.3% in Q2 2026 (SEC filing, September 18, 2026).
The outlook is cautious due to technical weakness and institutional outflows. Opportunities lie in the clean energy theme amid global investment, but risks include high volatility and concentrated portfolio strategy. The ETF's performance is tied to sector sentiment rather than traditional corporate fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
